Jason Kelly, Ginkgo Bioworks CEO (Kyle Grillot/Bloomberg via Getty Images)

Gink­go Bioworks ac­quires strug­gling syn­bio ri­val Zymer­gen in $300M all-stock deal

Gink­go Bioworks is pick­ing up a syn­thet­ic bi­ol­o­gy com­peti­tor in what it says is its largest M&A deal yet.

Gink­go put out word ear­ly Mon­day …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.